MedNet.nl: The outcomes and safety of axicabtagene ciloleucel (axi-cel) in patients with relapsing or refractory follicular lymphoma appear to be consistent with the outcomes and safety observed in the ZUMA-5 study in daily practice, despite a broader patient population.
22-06-2023 | Non-Hodgkin Lymphoma | Congress News | News
EHA 2023